Literature DB >> 20842541

Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery.

Sunil Kumar Battu1, Michael A Repka, Sindhuri Maddineni, Amar G Chittiboyina, Mitchell A Avery, Soumyajit Majumdar.   

Abstract

The objective of the present research was to evaluate the physicochemical characteristics of berberine chloride and to assess the complexation of drug with 2-hydroxypropyl-β-cyclodextrin (HPβCD), a first step towards solution dosage form development. The parameters such as log P value were determined experimentally and compared with predicted values. The pH-dependent aqueous solubility and stability were investigated following standard protocols at 25°C and 37°C. Drug solubility enhancement was attempted utilizing both surfactants and cyclodextrins (CDs), and the drug/CD complexation was studied employing various techniques such as differential scanning calorimetry, Fourier transform infrared, nuclear magnetic resonance, and scanning electron microscopy. The experimental log P value suggested that the compound is fairly hydrophilic. Berberine chloride was found to be very stable up to 6 months at all pH and temperature conditions tested. Aqueous solubility of the drug was temperature dependent and exhibited highest solubility of 4.05 ± 0.09 mM in phosphate buffer (pH 7.0) at 25°C, demonstrating the effect of buffer salts on drug solubility. Decreased drug solubility was observed with increasing concentrations of ionic surfactants such as sodium lauryl sulfate and cetyl trimethyl ammonium bromide. Phase solubility studies demonstrated the formation of berberine chloride-HPβCD inclusion complex with 1:1 stoichiometry, and the aqueous solubility of the drug improved almost 4.5-fold in the presence of 20% HPβCD. The complexation efficiency values indicated that the drug has at least threefold greater affinity for hydroxypropyl-β-CD compared to randomly methylated-β-CD. The characterization techniques confirmed inclusion complex formation between berberine chloride and HPβCD and demonstrated the feasibility of developing an oral solution dosage form of the drug.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842541      PMCID: PMC2974104          DOI: 10.1208/s12249-010-9520-y

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  33 in total

1.  Effect of pH-sodium lauryl sulfate combination on solubilization of PG-300995 (an anti-HIV agent): a technical note.

Authors:  Akash Jain; Yingqing Ran; Samuel H Yalkowsky
Journal:  AAPS PharmSciTech       Date:  2004-07-27       Impact factor: 3.246

2.  Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003).

Authors:  Jennifer M Streit; Ronald N Jones; Mark A Toleman; Leonid S Stratchounski; Thomas R Fritsche
Journal:  Int J Antimicrob Agents       Date:  2006-05       Impact factor: 5.283

3.  Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing.

Authors:  M Másson; T Loftsson; G Másson; E Stefánsson
Journal:  J Control Release       Date:  1999-05-01       Impact factor: 9.776

4.  Berberine inhibits ion transport in human colonic epithelia.

Authors:  C T Taylor; D C Winter; M M Skelly; D P O'Donoghue; G C O'Sullivan; B J Harvey; A W Baird
Journal:  Eur J Pharmacol       Date:  1999-02-26       Impact factor: 4.432

5.  Evaluation of cyclodextrin solubilization of drugs.

Authors:  Thorsteinn Loftsson; Dagný Hreinsdóttir; Már Másson
Journal:  Int J Pharm       Date:  2005-09-30       Impact factor: 5.875

6.  Berberine--a novel approach to cholesterol lowering.

Authors:  Sheila A Doggrell
Journal:  Expert Opin Investig Drugs       Date:  2005-05       Impact factor: 6.206

7.  Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry.

Authors:  Feng Zuo; Norio Nakamura; Teruaki Akao; Masao Hattori
Journal:  Drug Metab Dispos       Date:  2006-09-06       Impact factor: 3.922

8.  Antiviral activity of berberine and related compounds against human cytomegalovirus.

Authors:  Kyoko Hayashi; Kazuki Minoda; Yasuo Nagaoka; Toshimitsu Hayashi; Shinichi Uesato
Journal:  Bioorg Med Chem Lett       Date:  2007-01-04       Impact factor: 2.823

9.  Increase in action potential duration and inhibition of the delayed rectifier outward current IK by berberine in cat ventricular myocytes.

Authors:  J Sánchez-Chapula
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

10.  Lipoxygenase inhibition and antioxidant properties of protoberberine and aporphine alkaloids isolated from Mahonia aquifolium.

Authors:  V Misík; L Bezáková; L Máleková; D Kostálová
Journal:  Planta Med       Date:  1995-08       Impact factor: 3.352

View more
  40 in total

1.  Influence of process and formulation parameters on dissolution and stability characteristics of Kollidon® VA 64 hot-melt extrudates.

Authors:  Sindhuri Maddineni; Sunil Kumar Battu; Joe Morott; Soumyajit Majumdar; S N Murthy; Michael A Repka
Journal:  AAPS PharmSciTech       Date:  2014-11-01       Impact factor: 3.246

2.  Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats.

Authors:  Wei Chen; Yu-Qiang Miao; Dong-Jiao Fan; Shen-Shen Yang; Xia Lin; Ling-Kuo Meng; Xing Tang
Journal:  AAPS PharmSciTech       Date:  2011-06-03       Impact factor: 3.246

3.  In Vitro Activity of Berberine Alone and in Combination with Antifungal Drugs Against Planktonic Forms and Biofilms of Trichosporon Asahii.

Authors:  Lin Cong; Yong Liao; Suteng Yang; Rongya Yang
Journal:  Mycopathologia       Date:  2017-01-31       Impact factor: 2.574

4.  Fabrication, characterization and optimization of berberine-loaded PLA nanoparticles using coaxial electrospray for sustained drug release.

Authors:  Reza Ghaffarzadegan; Sepideh Khoee; Shamsali Rezazadeh
Journal:  Daru       Date:  2020-04-20       Impact factor: 3.117

5.  Antibacterial activity of a berberine nanoformulation.

Authors:  Hue Thi Nguyen; Tuyet Nhung Pham; Anh-Tuan Le; Nguyen Thanh Thuy; Tran Quang Huy; Thuy Thi Thu Nguyen
Journal:  Beilstein J Nanotechnol       Date:  2022-07-11       Impact factor: 3.272

Review 6.  Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends.

Authors:  Tapan Behl; Sukhbir Singh; Neelam Sharma; Ishrat Zahoor; Ali Albarrati; Mohammed Albratty; Abdulkarim M Meraya; Asim Najmi; Simona Bungau
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

7.  SN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer.

Authors:  Kiran Kumar Vangara; Hamed Ismail Ali; Dai Lu; Jingbo Louise Liu; Srikanth Kolluru; Srinath Palakurthi
Journal:  AAPS PharmSciTech       Date:  2014-01-30       Impact factor: 3.246

Review 8.  AMPK activation--protean potential for boosting healthspan.

Authors:  Mark F McCarty
Journal:  Age (Dordr)       Date:  2013-11-19

9.  Nanoformulation and Evaluation of Oral Berberine-Loaded Liposomes.

Authors:  Thuan Thi Duong; Antti Isomäki; Urve Paaver; Ivo Laidmäe; Arvo Tõnisoo; Tran Thi Hai Yen; Karin Kogermann; Ain Raal; Jyrki Heinämäki; Thi-Minh-Hue Pham
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

10.  Berberine-loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro.

Authors:  Keshav R Paudel; Meenu Mehta; Geena Hew Suet Yin; Lee Li Yen; Vamshikrishna Malyla; Vyoma K Patel; Jithendra Panneerselvam; Thiagarajan Madheswaran; Ronan MacLoughlin; Niraj Kumar Jha; Piyush Kumar Gupta; Sachin Kumar Singh; Gaurav Gupta; Pradeep Kumar; Brian G Oliver; Philip M Hansbro; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Environ Sci Pollut Res Int       Date:  2022-02-16       Impact factor: 5.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.